Structural Determinants of P-Glycoprotein-Mediated Transport of Glucocorticoids

Pharmaceutical Research

Volumn 20, Issue 11, 2003, Pages 1794-1803

  Yates, Charles R ^a   Chang, Cheng ^b,c   Kearbey, Jeffrey D ^b   Yasuda, Kazuto ^d   Schuetz, Erin G ^d   Miller, Duane D ^a   Dalton, James T ^b   Swaan, Peter W ^b,c  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Computational biopharmaceutics; Glucocorticoids; P glycoprotein

Indexed keywords

6ALPHA HYDROXYCORTISOL; 6BETA HYDROXYHYDROCORTISONE; BETAMETHASONE; DEXAMETHASONE; GLUCOCORTICOID; GLYCOPROTEIN P; HYDROCORTISONE; HYDROCORTISONE DERIVATIVE; METHYLPREDNISOLONE; PREDNISOLONE; PREDNISONE; UNCLASSIFIED DRUG; VERAPAMIL;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DIFFUSION; DRUG STRUCTURE; DRUG TRANSPORT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROGEN BOND; MOLECULAR MODEL; NONHUMAN; PARTITION COEFFICIENT; PHARMACOPHORE; PHENOTYPE; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; SWINE;

ANIMALS; BIOLOGICAL TRANSPORT; GLUCOCORTICOIDS; HUMANS; LLC-PK1 CELLS; MICE; MOLECULAR STRUCTURE; P-GLYCOPROTEIN; PHENOTYPE; SWINE;

EID: 0344084041     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:PHAM.0000003377.39548.f6     Document Type: Article

References (30)

1. O. C. Meijer, E. C. de Lange, D. D. Breimer, A. G. de Boer, J. O. Workel, and E. R. de Kloet. Penetration of dexamethasone into brain glucocorticoid targets is enhanced in mdr1A P-glycoprotein knockout mice. Endocrinology 139:1789-1793 (1998).
2. A. M. Karssen, O. C. Meijer, I. C. van der Sandt, P. J. Lucassen, E. C. de Lange, A. G. de Boer, and E. R. de Kloet. Multidrug resistance P-glycoprotein hampers the access of cortisol but not of corticosterone to mouse and human brain. Endocrinology 142: 2686-2694 (2001).
3. A. Nakayama, O. Eguchi, M. Hatakeyama, H. Saitoh, and M. Takada. Different absorption behaviors among steroid hormones due to possible interaction with P-glycoprotein in the rat small intestine. Biol. Pharm. Bull. 22:535-538 (1999).
4. S. Bourgeois, D. J. Gruol, R. F. Newby, and F. M. Rajah. Expression of an mdr gene is associated with a new form of resistance to dexamethasone- induced apoptosis. Mol. Endocrinol. 7: 840-851 (1993).
5. D. J. Gruoland S. Bourgeois. Chemosensitizing steroids: glucocorticoid receptor agonists capable of inhibiting P-glycoprotein function. Cancer Res. 57:720-727 (1997).
6. K. Ueda, N. Okamura, M. Hirai, Y. Tanigawara, T. Saeki, N. Kioka, T. Komano, and R. Hori. Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J. Biol. Chem. 267:24248-24252 (1992).
7. C. K. van Kalken, H. J. Broxterman, H. M. Pinedo, N. Feller, H. Dekker, J. Lankelma, and G. Giaccone. Cortisol is transported by the multidrug resistance gene product P-glycoprotein. Br. J. Cancer 67:284-289 (1993).
8. K. M. Barnes, B. Dickstein, G. B. Cutler Jr., T. Fojo, and S. E. Bates. Steroid treatment, accumulation, and antagonism of P-glycoprotein in multidrug-resistant cells. Biochemistry 35:4820-4827 (1996).
9. A. H. Schinkel, E. Wagenaar, L. van Deemter, C. A. Mol, and P. Borst. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J. Clin. Invest. 96:1698-1705 (1995).
10. S. I. Hsu, L. Lothstein, and S. B. Horwitz. Differential overexpression of three mdr gene family members in multidrug-resistant J774.2 mouse cells. Evidence that distinct P-glycoprotein precursors are encoded by unique mdr genes. J. Biol. Chem. 264:12053-12062 (1989).
11. L. Homolya, Z. Hollo, U. A. Germann, I. Pastan, M. M. Gottesman, and B. Sarkadi. Fluorescent cellular indicators are extruded by the multidrug resistance protein. J. Biol. Chem. 268:21493-21496 (1993).
12. J. M. Ford. Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers. Eur. J. Cancer 32A:991-1001 (1996).
13. C. R. Yates, A. Vysokanov, A. Mukherjee, T. M. Ludden, E. Tolley, G. U. Meduri, and J. T. Dalton. Time-variant increase in methylprednisolone clearance in patients with acute respiratory distress syndrome: a population pharmacokinetic study. J. Clin. Pharmacol. 41:415-424 (2001).
14. Y. C. Martin, M. G. Bures, E. A. Danaher, J. DeLazzer, I. Lico, and P. A. Pavlik. A fast new approach to pharmacophore mapping and its application to dopaminergic and benzodiazepine agonists. J. Comput. Aided Mol. Des. 7:83-102 (1993).
15. R. T. Kroemer, E. Koutsilieri, P. Hecht, K. R. Liedl, P. Riederer, and J. Kornhuber. Quantitative analysis of the structural requirements for blockade of the N-methyl-D-aspartate receptor at the phencyclidine binding site. J. Med. Chem. 41:393-400 (1998).
16. R. S. Bohacek and C. McMartin. Definition and display of steric, hydrophobic, and hydrogen-bonding properties of ligand binding sites in proteins using Lee and Richards accessible surface: validation of a high-resolution graphical tool for drug design. J. Med. Chem. 35:1671-1684 (1992).
17. G. Klebe, U. Abraham, and T. Mietzner. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J. Med. Chem. 37: 4130-4146 (1994).
18. M. Torok, H. Gutmann, G. Fricker, and J. Drewe. Sister of P-glycoprotein expression in different tissues. Biochem. Pharmacol. 57:833-835 (1999).
19. R. J. Raggers, A. van Helvoort, R. Evers, and G. van Meer. The human multidrug resistance protein MRP1 translocates sphingolipid analogs across the plasma membrane. J. Cell Sci. 112(Pt 3):415-422 (1999).
20. P. Wils, A. Warnery, V. Phung-Ba, S. Legrain, and D. Scherman. High lipophilicity decreases drug transport across intestinal epithelial cells. J. Pharmacol. Exp. Ther. 269:654-658 (1994).
21. G. H. Rothblat and M. C. Phillips. Mechanism of cholesterol efflux from cells. Effects of acceptor structure and concentration. J. Biol. Chem. 257:4775-4782 (1982).
22. B. A. Luxonand R. A. Weisiger. A new method for quantitating intracellular transport: application to the thyroid hormone 3,5,3′- triiodothyronine. Am. J. Physiol. 263:G733-G741 (1992).
23. M. Clarkand R. D. Cramer III. The Probability of Chance Correlation Using Partial Least Squares (PLS). Quant. Struct.-Act. Relat. 12:137-145 (1993).
24. D. J. Gruol, Q. D. Vo, and M. C. Zee. Profound differences in the transport of steroids by two mouse P-glycoproteins. Biochem. Pharmacol. 58:1191-1199 (1999).
25. S. Ekins, R. B. Kim, B. F. Leake, A. H. Dantzig, E. G. Schuetz, L. B. Lan, K. Yasuda, R. L. Shepard, M. A. Winter, J. D. Schuetz, J. H. Wikel, and S. A. Wrighton. Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol. Pharmacol. 61:964-973 (2002).
26. S. Ekins, R. B. Kim, B. F. Leake, A. H. Dantzig, E. G. Schuetz, L. B. Lan, K. Yasuda, R. L. Shepard, M. A. Winter, J. D. Schuetz, J. H. Wikel, and S. A. Wrighton. Application of three-dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates. Mol. Pharmacol. 61:974-981 (2002).
27. H. Saitoh, M. Hatakeyama, O. Eguchi, M. Oda, and M. Takada. Involvement of intestinal P-glycoprotein in the restricted absorption of methylprednisolone from rat small intestine. J. Pharm. Sci. 87:73-75 (1998).
28. K. L. Koszdin, D. D. Shen, and C. M. Bernards. Spinal cord bioavailability of methylprednisolone after intravenous and intrathecal administration: the role of P-glycoprotein. Anesthesiology 92:156-163 (2000).
29. G. L. Flynn. Structural approach to partitioning: Estimation of steroid partition coefficients based upon molecular constitution. J. Pharm. Sci. 60:345-353 (1971).
30. A. Leo, C. Hansch, and D. Elkins. Partition coefficients and their uses. Chem. Rev. 71:525-616 (1971).